Wall Street analysts expect Core Laboratories (NYSE:CLB) to report $0.58 earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for Core Laboratories’ earnings. Core Laboratories reported earnings of $0.41 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.5%. The business is expected to report its next quarterly earnings results on Wednesday, January 24th.
According to Zacks, analysts expect that Core Laboratories will report full-year earnings of $1.99 per share for the current financial year, with EPS estimates ranging from $1.95 to $2.00. For the next fiscal year, analysts expect that the firm will report earnings of $2.70 per share, with EPS estimates ranging from $2.38 to $2.92. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Core Laboratories.
Core Laboratories (NYSE:CLB) last posted its earnings results on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.04. The firm had revenue of $166.20 million during the quarter, compared to the consensus estimate of $160.94 million. Core Laboratories had a net margin of 12.06% and a return on equity of 52.89%. The company’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.38 EPS.
CLB has been the subject of a number of research analyst reports. Loop Capital dropped their target price on shares of Core Laboratories from $125.00 to $115.00 and set a “buy” rating for the company in a research report on Wednesday, October 25th. Royal Bank of Canada lowered their price objective on shares of Core Laboratories from $115.00 to $112.00 and set an “outperform” rating for the company in a research report on Thursday, September 7th. ValuEngine downgraded shares of Core Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Cowen reaffirmed a “hold” rating and issued a $100.00 price objective on shares of Core Laboratories in a research report on Friday, September 1st. Finally, Zacks Investment Research raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research report on Tuesday, September 12th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. Core Laboratories currently has an average rating of “Hold” and an average target price of $110.20.
A number of hedge funds have recently bought and sold shares of CLB. The Manufacturers Life Insurance Company lifted its stake in Core Laboratories by 63.7% in the second quarter. The Manufacturers Life Insurance Company now owns 1,128 shares of the oil and gas company’s stock valued at $114,000 after buying an additional 439 shares during the last quarter. Advisory Services Network LLC lifted its stake in Core Laboratories by 33.3% in the second quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock valued at $138,000 after buying an additional 341 shares during the last quarter. Toronto Dominion Bank lifted its stake in Core Laboratories by 243.6% in the third quarter. Toronto Dominion Bank now owns 1,866 shares of the oil and gas company’s stock valued at $184,000 after buying an additional 1,323 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Core Laboratories in the second quarter valued at $203,000. Finally, Park National Corp OH bought a new stake in shares of Core Laboratories during the third quarter valued at about $209,000.
Core Laboratories (NYSE:CLB) traded up $1.00 on Friday, reaching $109.55. 390,061 shares of the company were exchanged, compared to its average volume of 461,442. The firm has a market cap of $4,792.20, a P/E ratio of 62.96 and a beta of 1.56. Core Laboratories has a 12-month low of $86.55 and a 12-month high of $125.83. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.81 and a current ratio of 2.18.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Core Laboratories (CLB) to Announce $0.58 EPS” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/zacks-brokerages-anticipate-core-laboratories-clb-to-announce-0-58-eps-updated.html.
Core Laboratories Company Profile
Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.